TCWA
CSTL icon

Ten Capital Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

Ten Capital Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,376
Closed -$31.3K – 253
2023
Q1 		$31.3K Hold
1,376
– – 0.01% 268
2022
Q4 		$32.4K Buy
+1,376
New +$31.9K 0.01% 213

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ten Capital Wealth Advisors's CSTL Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 1,376 shares — an estimated $31.3K sold.

Ten Capital Wealth Advisors first reported a position in CSTL in Q4 2022 and held it in 2 quarters. The position peaked at $32.4K in Q4 2022. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 1,376 Castle Biosciences shares in Q2 2023, an estimated $31.3K.
  • Ten Capital Wealth Advisors first reported a position in Castle Biosciences in Q4 2022 and held it in 2 quarters.
  • Ten Capital Wealth Advisors's Castle Biosciences position peaked at $32.4K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.